Search Results (2)

TiB₂–MgAl₂O₄ composites were fabricated by combustion synthesis involving metallothermic reduction reactions. Thermite reagents contained Al and Mg as dual reductants and TiO₂ or B₂O₃ as the oxidant. The reactant mixtures also comprised elemental Ti and boron, as well as a small amount of Al₂O₃ or MgO to serve as the combustion moderator. Four reaction systems were conducted and all of them were exothermic enough to proceed in the mode of self-propagating high-temperature synthesis (SHS). The reaction based on B₂O₃/Al/Mg thermite and diluted with MgO was the most exothermic, while that containing TiO₂/Al/Mg thermite and Al₂O₃ as the diluent was the least. Depending on different thermites and diluents, the combustion front temperatures in a range from 1320 to 1720 °C, and combustion wave velocity from 3.9 to 5.7 mm/s were measured. The XRD spectra confirmed in situ formation of TiB₂ and MgAl₂O₄. It is believed that MgAl₂O₄ was synthesized through a combination reaction between Al₂O₃ and MgO, both of which can be totally or partially produced from the metallothermic reduction of B₂O₃ or TiO₂. The microstructure of the TiB₂–MgAl₂O₄ composite exhibited fine TiB₂ crystals surrounded by large densified MgAl₂O₄ grains. This study demonstrated an energy-saving and efficient route for fabricating MgAl₂O₄-containing composites. Full article

Oseltamivir phosphate (OP) is an antiviral drug available only as oral therapy for the treatment of influenza and as a potential treatment option when in combination with other medication in the fight against the corona virus disease (COVID-19) pneumonia. In this study, OP was formulated as a dry powder for inhalation, which allows drug targeting to the site of action and potentially reduces the dose, aiming a more efficient therapy. Binary formulations were based on micronized excipient particles acting like diluents, which were blended with the drug OP. Different excipient types, excipient ratios, and excipient size distributions were prepared and examined. To investigate the feasibility of delivering high doses of OP in a single dose, 1:1, 1:3, and 3:1 drug/diluent blending ratios have been prepared. Subsequently, the aerosolization performance was evaluated for all prepared formulations by cascade impaction using a novel medium-resistance capsule-based inhaler (UNI-Haler). Formulations with micronized trehalose showed relatively excellent aerosolization performance with highest fine-particle doses in comparison to examined lactose, mannitol, and glucose under similar conditions. Focusing on the trehalose-based dry-powder inhalers’ (DPIs) formulations, a physicochemical characterization of extra micronized grade trehalose in relation to the achieved performance in dispersing OP was performed. Additionally, an early indication of inhaled OP safety on lung cells was noted by the viability MTT assay utilizing Calu-3 cells. Full article